APA (7th ed.) Citation

Taneda, S., Hyllested‐Winge, J., Gall, M., Kaneko, S., & Hirao, K. (2017). Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin‐experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan‐Asian, treat‐to‐target Phase 3 Trial. Journal of diabetes, 9(3), 243-247. https://doi.org/10.1111/1753-0407.12407

Chicago Style (17th ed.) Citation

Taneda, Shinji, Jacob Hyllested‐Winge, Mari‐Anne Gall, Shizuka Kaneko, and Koichi Hirao. "Insulin Degludec/insulin Aspart Versus Biphasic Insulin Aspart 30 Twice Daily in Insulin‐experienced Japanese Subjects with Uncontrolled Type 2 Diabetes: Subgroup Analysis of a Pan‐Asian, Treat‐to‐target Phase 3 Trial." Journal of Diabetes 9, no. 3 (2017): 243-247. https://doi.org/10.1111/1753-0407.12407.

MLA (9th ed.) Citation

Taneda, Shinji, et al. "Insulin Degludec/insulin Aspart Versus Biphasic Insulin Aspart 30 Twice Daily in Insulin‐experienced Japanese Subjects with Uncontrolled Type 2 Diabetes: Subgroup Analysis of a Pan‐Asian, Treat‐to‐target Phase 3 Trial." Journal of Diabetes, vol. 9, no. 3, 2017, pp. 243-247, https://doi.org/10.1111/1753-0407.12407.